Classical Hematology

The new data demonstrates the effectiveness of Mim8 in children with hemophilia A regardless of inhibitor status, expanding the populations in which the novel drug in development could have a treatment benefit.

Improvements in baseline for markers of hemolysis (indirect bilirubin, lactate dehydrogenase, and haptoglobin) were observed only in the mitapivat arm.

Prescribing and dosing appropriate treatments for patients with sickle cell disease while managing episodes of acute pain are some of the integral roles of pharmacists.

Steven Pipe, MD, explains the long-term efficacy data surrounding etranacogene dezaparvovec in patients with hemophilia B.

A one-time infusion of etranacogene dezaparvovec-drlb led to sustained bleeding control and a reduction in factor IX prophylaxis in patients with hemophilia B.

Thalassemia, a chronic blood condition that reduces hemoglobin levels, requires a hands-on approach from pharmacists in patient monitoring and diagnosis.

Pharmacists should educate patients on abelacimab's potential therapeutic impact on atrial fibrillation patients at risk of stroke.

Higher p16 expression in patients with sickle cell disease led to heightened risk of age-related complications.

Christian Ruff explains the strong efficacy associated with abelacimab compared with rivaroxaban in the AZALEA-TIMI 71 trial.

Fitusiran is part of a generation of novel RNA interference therapies and is designed for subcutaneous administration for the prophylactic treatment of hemophilia A or B.

Pharmacists can improve hyperkalemia management through collaboration and innovation.

Abelacimab (Anthos Therapeutics Inc) is a novel factor XI inhibitor being investigated for the reduction of bleeding for patients with atrial fibrillation.

Multiple treatments have been approved by regulators for the treatment of hemophilia A and B, giving pharmacists options for their patients.

These drugs are set to revolutionize their respective disease states in 2025.

High-cost medications necessary for treatment require close management to ensure patient safety and to adhere to payer-specific requirements.

Data from a follow-up at 6 months show a reduced risk of all-cause mortality in heart attack patients with anemia who receive a liberal transfusion strategy compared with a restrictive one.

Pharmacists should be aware of the impacts that anemia in patients being treated for cancer has on daily activities and overall quality of life.

Gecacitinib is a novel inhibitor targeting both JAK and ACVR1.

Concizumab-mtci is a subcutaneous, monoclonal antibody designed to achieve hemostasis in all hemophilia types.

Anemia is a common adverse effect of ruxolitinib, calling for new approaches to mitigate risks.

Clinical trial analysis results studying VAD-44 in patients with hereditary hemorrhagic telangiectasia (HTT) will be presented at the 2024 American Society of Hematology Annual Meeting & Exposition.

Intravenous immunoglobulin prescriptions deemed non-compliant according to French national guidelines were more common in younger patients.

Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.

This approval marks the first and only anti-tissue factor pathway inhibitor approved in the US for the treatment hemophilia A or B, and the first approved hemophilia treatment to be administered via a pre-filled, auto-injector pen.

By utilizing a lower dose, patients can avoid potential adverse events and high financial burden.